Alterity Therapeutics (ATHE) Common Equity (2009 - 2026)

Alterity Therapeutics has reported Common Equity for 18 years, with the latest figure at $30.3 million in Q2 2026.

• On a quarterly basis, Common Equity rose 11.6% year-over-year to $30.3 million in Q2 2026; TTM through Jun 2026 was $30.3 million, a 11.6% increase from a year earlier, with the FY2026 full-year figure at $30.3 million, up 11.6% from the prior year.
• Common Equity was $30.3 million for Q2 2026 at Alterity Therapeutics, down from $35.6 million in the prior quarter.
• The five-year high for Common Equity was $35.6 million in Q4 2025, with the low at $137980.6 in Q2 2024.
• Average Common Equity over 5 years is $17.1 million, with a median of $18.5 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Common Equity slumped 99.1% in 2023, then surged 19581.28% in 2025.
• Over 5 years, Common Equity stood at $18.5 million in 2022, then sank by 37.87% to $11.5 million in 2023, then plunged by 55.62% to $5.1 million in 2024, then surged by 599.79% to $35.6 million in 2025, then decreased by 14.94% to $30.3 million in 2026.
• The last three Common Equity figures came in at $30.3 million (Q2 2026), $35.6 million (Q4 2025), and $27.2 million (Q2 2025), per Business Quant data.